SCHEMBL4514508

SCHEMBL4514508

C1=Cc2c3c(ccc2=N1)=Nc1ccccc1-3

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8880037 0.85
SCHEMBL9959991 0.78 IDO1 (0.39) IDO1
SCHEMBL4511998 0.75 IDO1 (0.30) IDO1
SCHEMBL4499356 0.74
SCHEMBL17766690 0.72 GSK3A (0.36) IDO1
SCHEMBL4491305 0.71
SCHEMBL29441962 0.68
SCHEMBL4501349 0.68 IDO1 (0.30) IDO1
SCHEMBL4488526 0.67
SCHEMBL4495883 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110003085-A Luxuriant and rich with fragrance [3,4-f] benzazolyl compounds of 12- hexyl -12H- and its synthetic method and application 山东大学 2019-07-12 CN disclosed
CN-109422750-A The synthesis and application of natural products Dicododendrin and its derivative 重庆大学 2019-03-05 CN disclosed
CN-104703989-B New compound and the organic electroluminescent device comprising it 株式会社斗山 2017-09-29 CN disclosed
CN-104703989-A Novel compound and organic electroluminescence device comprising same DOOSAN CORP 2015-06-10 CN disclosed
US-8252814-B2 Agents and crystals for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-28 US disclosed
US-20090264467-A1 Agents and crystals for improving excretory potency of urinary bladder ISHIHARA YUJI 2009-10-22 US disclosed
US-7462628-B2 Preventives/remedies for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-09 US disclosed
EP-1891954-A2 Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder Takeda Pharmaceutical Company Limited (JP) 2008-02-27 EP disclosed
US-20070232538-A1 Uses of polypeptides TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) 2007-10-04 US disclosed
US-20070021391-A1 Preventive/remedy for urinary disturbance TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-25 US disclosed
US-6534496-B1 Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2003-03-18 US disclosed
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2002-11-28 US disclosed
EP-1118322-A1 DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH Takeda Chemical Industries, Ltd. (JP) 2001-07-25 EP disclosed
EP-0885229-B1 FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON CEPHALON INC (US) 2000-08-02 EP disclosed
EP-0975624-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS Takeda Chemical Industries, Ltd. (JP) 2000-02-02 EP disclosed
EP-0885229-A1 FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON CEPHALON, INC. (US) 1998-12-23 EP disclosed
WO-1998046590-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-22 WO disclosed
WO-1997031002-A1 FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON CEPHALON, INC. (US) 1997-08-28 WO disclosed
US-5616724-A FOR POTENTIATION OF HUMAN INTERFERON-GAMMA; IMMUNOLOGY CEPHALON, INC. (US) 1997-04-01 US disclosed
EP-0655451-A1 Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021391-A1 Preventive/remedy for urinary disturbance ACHE, BCHE, CHAT IDO1 2422/4885
US-20090264467-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BCHE, PDE7A IDO1 650/4885
US-20020177593-A1 Agents and crystals for improving excretory potency of urinary bladder ACHE, BPHL, BCHE IDO1 583/4885
US-20070232538-A1 Uses of polypeptides NPSR1, SCTR, GRPR IDO1 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.